Inflammation and Atherosclerosis: Prospects for Clinical Trials.
作者信息
Ait-Oufella Hafid, Libby Peter
机构信息
Université Paris Cité, INSERM U970, Paris Cardiovascular Research Center (H.A.-O.), Sorbonne Université, France.
Medical Intensive Care Unit, Hôpital Saint-Antoine, AP-HP (H.A.-O.), Sorbonne Université, France.
出版信息
Arterioscler Thromb Vasc Biol. 2024 Sep;44(9):1899-1905. doi: 10.1161/ATVBAHA.124.320155. Epub 2024 Aug 21.
Abstract
摘要
相似文献
1
Inflammation and Atherosclerosis: Prospects for Clinical Trials.
Arterioscler Thromb Vasc Biol. 2024 Sep;44(9):1899-1905. doi: 10.1161/ATVBAHA.124.320155. Epub 2024 Aug 21.
2
Targeting the immune response in atherosclerosis: It's time for clinical trials!
Arch Cardiovasc Dis. 2017 Dec;110(12):643-645. doi: 10.1016/j.acvd.2017.08.001. Epub 2017 Oct 16.
3
Inflammation and atherosclerosis: what is on the horizon?
Heart. 2020 Jan;106(1):80-85. doi: 10.1136/heartjnl-2018-314230.
4
Targeting inflammation in cardiovascular diseases. still a neglected field?
Cardiovasc Ther. 2012 Aug;30(4):e189-97. doi: 10.1111/j.1755-5922.2011.00274.x. Epub 2011 Apr 1.
5
Inflammation in atherosclerosis: transition from theory to practice.
Circ J. 2010 Feb;74(2):213-20. doi: 10.1253/circj.cj-09-0706. Epub 2010 Jan 9.
6
Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
Cardiovasc Res. 2021 Jan 21;117(2):411-422. doi: 10.1093/cvr/cvaa211.
7
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions.
Atherosclerosis. 2018 Sep;276:98-108. doi: 10.1016/j.atherosclerosis.2018.07.014. Epub 2018 Jul 25.
8
IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles.
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):258-64. doi: 10.1161/ATVBAHA.114.303567. Epub 2014 Sep 18.
9
Inflammation and atherosclerosis--revisited.
J Cardiovasc Pharmacol Ther. 2014 Mar;19(2):170-8. doi: 10.1177/1074248413504994. Epub 2013 Oct 31.
10
Atherosclerosis revisited from a clinical perspective: still an inflammatory disease?
Thromb Haemost. 2017 Jan 26;117(2):231-237. doi: 10.1160/TH16-10-0770. Epub 2016 Dec 15.
引用本文的文献
1
Prognostic implications of systemic immune-inflammation index and systemic inflammation response index in hemodialysis patients.
BMC Nephrol. 2025 Jul 1;26(1):322. doi: 10.1186/s12882-025-04223-y.
2
Transcriptomic signatures of atheroresistance in the human atrium and ventricle highlight potential candidates for targeted atherosclerosis therapeutics.
Biochem Biophys Rep. 2025 Apr 8;42:102007. doi: 10.1016/j.bbrep.2025.102007. eCollection 2025 Jun.
3
Role of Inflammatory and Proresolving Mediators in Endothelial Dysfunction.
Basic Clin Pharmacol Toxicol. 2025 May;136(5):e70026. doi: 10.1111/bcpt.70026.
4
Atherosclerosis: A Comprehensive Review of Molecular Factors and Mechanisms.
Int J Mol Sci. 2025 Feb 6;26(3):1364. doi: 10.3390/ijms26031364.
5
Vaccination as a Promising Approach in Cardiovascular Risk Mitigation: Are We Ready to Embrace a Vaccine Strategy?
Biomolecules. 2024 Dec 20;14(12):1637. doi: 10.3390/biom14121637.
6
Perivascular adipose tissue: a central player in the triad of diabetes, obesity, and cardiovascular health.
Cardiovasc Diabetol. 2024 Dec 28;23(1):455. doi: 10.1186/s12933-024-02549-9.
7
Estimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?
Eur Heart J Cardiovasc Imaging. 2025 Mar 3;26(3):444-460. doi: 10.1093/ehjci/jeae314.
8
Advanced Lung Cancer Inflammation Index as Predictor of All-Cause Mortality in ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention.
J Clin Med. 2024 Oct 11;13(20):6059. doi: 10.3390/jcm13206059.
本文引用的文献
1
Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial.
Cardiovasc Res. 2024 May 29;120(7):678-680. doi: 10.1093/cvr/cvae057.
2
B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans.
Sci Transl Med. 2024 Mar 6;16(737):eadi0295. doi: 10.1126/scitranslmed.adi0295.
3
Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease.
NEJM Evid. 2022 Jan;1(1):EVIDoa2100009. doi: 10.1056/EVIDoa2100009. Epub 2021 Nov 22.
4
High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction.
J Lipid Res. 2023 Jun;64(6):100391. doi: 10.1016/j.jlr.2023.100391. Epub 2023 May 19.
5
The why and how of adaptive immune responses in ischemic cardiovascular disease.
Nat Cardiovasc Res. 2022 May;1:431-444. doi: 10.1038/s44161-022-00049-1. Epub 2022 Apr 21.
6
CAR T cells produced in vivo to treat cardiac injury.
Science. 2022 Jan 7;375(6576):91-96. doi: 10.1126/science.abm0594. Epub 2022 Jan 6.
7
Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect.
Cardiovasc Res. 2021 Nov 22;117(13):2563-2574. doi: 10.1093/cvr/cvab309.
8
Humoral immunity in atherosclerosis and myocardial infarction: from B cells to antibodies.
Cardiovasc Res. 2021 Nov 22;117(13):2544-2562. doi: 10.1093/cvr/cvab285.
9
The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.
Eur Heart J. 2021 Nov 7;42(42):4389-4400. doi: 10.1093/eurheartj/ehab447.
10
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet. 2021 May 29;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1. Epub 2021 May 17.
Zotero 插件